ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
about
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerAcalabrutinib (ACP-196): a selective second-generation BTK inhibitorSecond-generation inhibitors of Bruton tyrosine kinaseEmerging therapies for acute myeloid leukemia.The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling.Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemiaCombined deletion of Xrcc4 and Trp53 in mouse germinal center B cells leads to novel B cell lymphomas with clonal heterogeneitySynergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions.Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia modelsA rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient.Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG.Leishmania donovani-Induced Increase in Macrophage Bcl-2 Favors Parasite Survival.Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.Gene mutations and actionable genetic lesions in mantle cell lymphoma.Richter Transformation of Chronic Lymphocytic Leukemia: A Review of Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography and Molecular DiagnosticsDevelopment of venetoclax for therapy of lymphoid malignancies.Mcl-1 expression and JNK activation induces a threshold for apoptosis in Bcl-xL-overexpressing hematopoietic cells.ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function.Non-Hodgkin and Hodgkin lymphomas select for overexpression of BCLW.Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.The safety of treatment options for elderly people with acute myeloid leukemia.New targeted therapies for malignant lymphoma based on molecular heterogeneity.The development of targeted new agents to improve the outcome for children with leukemia.Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.Treatment of Elderly Patients With Acute Myeloid Leukemia.Diagnosis and treatment of CD20 negative B cell lymphomas.Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.Treatment of Low-Blast Count AML using Hypomethylating Agents.Syk inhibitors in clinical development for hematological malignancies.Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.A general model for predicting the binding affinity of reversibly and irreversibly dimerized ligands.Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.Post-Transcriptional Regulation of Anti-Apoptotic BCL2 Family Members.
P2860
Q26748851-63D30047-DE3A-4E7B-AA5E-828D705BC443Q28066316-942FA03F-105A-42BA-A4CD-6AED19D8CFA5Q28076118-10F385E7-9BD4-4AF9-9DBC-146A7532238FQ33576363-E2BC62D1-4AF5-47F6-AF5A-B62206A032D5Q33629783-C2FCA135-1C3C-43AA-9321-112823E80281Q33648911-B915CB0A-6FDE-401E-8A8A-37A96535B41FQ36439752-773A69C8-0ACB-48A5-8772-6AD24DD46739Q36591877-2DFAC294-4EC9-4CCE-A7E3-38CF7E515B2EQ36735325-6CE80437-79C9-45C2-9027-F026133F15BCQ37045295-22964409-1AE2-469A-8EF3-894BA8CA3D28Q37119773-6316892B-75B4-43FE-AC01-9BF75F744DC3Q37129564-DF299C8C-26CF-4CA8-ACB1-A3604453BADBQ37363354-C754125D-D892-41EF-A0AF-241E935C82B5Q37399378-5B9413AB-410C-46FF-87FE-53033BE24C16Q37619710-D17662CA-0D14-4D36-A11D-D1B5DC695443Q37629080-5B13079B-8CCA-4C9F-B852-E96FAE63C731Q37632830-8CC9588E-3047-44FB-B503-24C80CC5DBF8Q37702281-396FAE5B-0570-4DCD-B774-F4E720913157Q37706871-232956E4-B18B-4F14-A7C2-48862E80F436Q37712188-152CCA4D-3533-4960-A3D9-F414CA440F36Q38599086-8FCFEB52-5560-4D90-AC3D-102F301665D9Q38601661-3ED20A80-1C9D-47E6-8974-C9A61E64DF19Q38722012-3E836B15-5AA0-4C4E-AA88-9B33ECCC6226Q38748203-8BAF3E83-F6BD-4399-9B63-918AB90D2DA8Q38760822-AC872B3D-FEAD-4A69-BACC-4BFD358F7A75Q38787141-089D015C-C8E4-4C76-9B70-8F33546A598FQ38964974-AF671A74-BC65-4EF0-8BA9-93339208BD74Q38988061-91993533-C673-458C-BEAC-93A97140EBDBQ38989496-545D9DB0-0052-43FB-BBEE-00786C52CF1BQ39112940-9EDB781B-B61E-4E52-B27D-8D77A26BEC63Q39132786-52F8514E-27A6-4EC5-A829-F8B896DDC4A9Q39200835-5FF42180-4040-47FA-93D9-8931F8E97863Q39429687-5DDA8A04-D771-4C4E-A818-C2A040B8027DQ42011012-5F653C4F-E545-415D-BC8C-5BDD6C0FC6ECQ42503679-11238A82-9D45-4421-B2D7-065642397C47Q45120868-5B52FB2B-1168-475B-AE35-C09A8F9A6D39Q45344868-3746BD56-4E9C-4E6D-B168-4430B22BAAF6Q46640442-913F5A57-B815-4228-8568-849B8A30D246Q47567993-69963DA9-81BE-4F30-B752-1C51C59F8829Q47716556-9B4342FB-CF6E-4F0A-A6B9-5ED13C85833E
P2860
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
@en
type
label
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
@en
prefLabel
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
@en
P2093
P2860
P921
P1476
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
@en
P2093
Chaitanya Iragavarapu
Delong Liu
John Savooji
Shundong Cang
Yongping Song
P2860
P2888
P356
10.1186/S13045-015-0224-3
P5008
P577
2015-11-20T00:00:00Z
P5875
P6179
1020159287